

Sub C2
1. (AMENDED) A method for *in vivo* delivery of a desired composition into a human or animal central nervous system (CNS) or spinal cord, comprising administering to the human or animal a composition comprising a non-toxic, proteolytic fragment of tetanus toxin (TT) in association with at least a molecule having a biological function, wherein said molecule with a biological function comprises a protein, and wherein said composition is capable of *in vivo* retrograde axonal transport and transynaptic transport into the CNS or the spinal cord of the human or animal and of being delivered at different areas of the spinal cord.

B2
6. (AMENDED) The method according to claim 1, wherein the non-toxic, proteolytic fragment of tetanus toxin (TT) comprises a fragment C and a fraction of fragment B of at least 11 amino acid residues, and the molecule having a biological function comprises a protein for compensation or modulation of functions under the control of the CNS or the spinal cord or modulation of functions in the CNS or the spinal cord.

7. (AMENDED) The method according to claim 1, wherein the non-toxic, proteolytic fragment of tetanus toxin (TT) comprises a fragment C and a fraction of fragment B of at least 11 amino acid residues, and the molecule having a biological function comprises a protein for the compensation or the modulation of functions under the control of the CNS or the spinal cord.

Sub B3
31. (AMENDED) A method for the treatment of the central nervous system (CNS) or spinal cord disease comprising:

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000